Related Experiment Video

Updated: Jan 25, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K

Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors

Rongfei Liu1, Jinghui Qi1, Yue Liu2

  • 1School of Pharmacy, Shandong Second Medical University, Weifang, Shandong 261053, PR China.

International Immunopharmacology
|January 23, 2026
PubMed

Insights

Abnormalities in protein tyrosine kinases (PTKs) drive cancer. This review focuses on fibroblast growth factor receptor (FGFR) inhibitors, crucial for future cancer therapy design and synthesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Protein tyrosine kinases (PTKs) are critical regulators of cellular processes, and their abnormalities are implicated in cancer development.
  • Fibroblast growth factor receptors (FGFRs), a subfamily of PTKs, play a significant role in tumorigenesis due to abnormal intracellular expression.
  • Targeting FGFRs presents a promising therapeutic strategy for various cancers.

Purpose of the Study:

  • To review and summarize recent advancements in the field of FGFR inhibitors.
  • To provide insights into the design and synthesis of novel FGFR inhibitors for cancer treatment.

Main Methods:

  • Literature review of recent research on FGFR inhibitors.
  • Analysis of studies focusing on the therapeutic potential of FGFR inhibitors in cancer.

Main Results:

  • FGFRs are key therapeutic targets in cancer treatment due to their role in tumorigenesis.
  • Recent research has yielded significant progress in the development of FGFR inhibitors.
  • These inhibitors show promise for future cancer therapy.

Conclusions:

  • FGFR inhibitors represent a vital area of research for developing new cancer treatments.
  • Continued investigation into FGFR inhibitors is essential for advancing targeted cancer therapy.
  • This review offers insights for the future design and synthesis of effective FGFR inhibitors.
Keywords:
Cancer therapyFGFRInhibitorSmall-molecule derivativesStructural optimization

More Related Videos

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

11.3K
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

27.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
584
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
481
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.3K